X hits on this document

707 views

0 shares

0 downloads

0 comments

71 / 170

14

with regards to the sub-groups. Due to the small number of events within the sub-groups,

15

one would not expect, there to be power to observe interactions that might be clinically

16

relevant and we did not see any.

5

DR. WOLF: We will have to look at that during the break.

6

DR. WYNE: Okay, thank you.

7

DR. BURMAN: Thank you. One more question Mike.

8

DR. PROSCHAN: With respect to all those different cardiovascular

19

questions that we had earlier, I wanted the committee to be aware that the Sponsors are

20

currently conducting a randomized clinical trial in patients with moderate and severe

21

renal sufficiency. Those data, I mean that study is still ongoing at this time.

17

DR. BURMAN: Thank you very much.

18

DR. WOLF: If I could, I just wanted to finish a response to one of the

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

9

outcomes you have had, were any of the tests for heterogeneity of the risk ratios, did any

10

of those come out significant? I think I know the answer to this.

1

DR. WOLF: We will get the data for you on the percent use of Statin

70

2

and the second question?

12

13

address that question.

DR. HENRY: David Henry, Biostatistics, Bristol-Myers Squibb. This is

22

23

DR. BURMAN: Thank you. We will now proceed with our presentation

from the FDA. I would like to remind public observers at this meeting that while this

11

DR. WOLF: I think I will ask Dr. Dave Henry to come to the podium to

3

4

DR. WYNE: Just if there was any specific Statins, I guess to go with it is

actually the Statin-fibrate combination also.

Document info
Document views707
Page views707
Page last viewedTue Jan 24 05:56:33 UTC 2017
Pages170
Paragraphs7975
Words54271

Comments